BioSpace News Archive

Drug Development

ASGCT: Rocket Ready to Launch, Mustang Bio’s Successful Trial and Voyager’s Early Data

The 25th Annual Meeting of the American Society of Gene and Cell Therapy wrapped up on Thursday. BioSpace looks at some of the highlights.

May 20, 2022
·
3 min read
·
Hayley Shasteen
TRK Inhibitors Market Size Drug Sales Clinical Trials Insight 2026

Recently, researchers have characterized the biological significance of gene fusions as a potential molecular targeted therapy owing to their high specificity and selectivity towards the cancer cell.

May 20, 2022
·
3 min read
Researchers Develop CRISPR Mechanism to Edit Multiple DNA Sites at Once

Rice University researchers used the foundation of CRISPR/Cas9 technology and developed “drive-and-process” arrays, or DAP for short.

May 20, 2022
·
2 min read
·
Jazmine Colatriano
Bio NC

Inceptor Bio Snags $37M for Three-Pronged Immuno-Oncology Platforms

Fueled by $37 million in Series A financing, N.C.-based Inceptor Bio is advancing three, next-generation approaches to immuno-oncology, including a CAR-T program that is expected to be in the clinic next year.

May 20, 2022
·
4 min read
·
Alex Keown
Zymeworks Board Rejects All Blue’s “Opportunistic” Acquisition Proposal

The Zymeworks Board of Directors has rejected an acquisition proposal from activist investor All Blue Falcons FZE, calling the attempt “opportunistic.”

May 20, 2022
·
3 min read
·
Alex Keown
Drug Development

Clinical Catch-Up: Amgen, AstraZeneca, Avillion Attack Asthma

Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.

May 20, 2022
·
10 min read
·
Mark Terry
Business

Bayer Terminates CAR-T Collaboration with Atara Therapeutics

Bayer has terminated a two year-old partnership with Atara to develop off-the-shelf T-cell immunotherapy for high mesothelin-expressing tumors.

May 20, 2022
·
3 min read
·
Alex Keown
Drug Development

BridgeBio Continues Comeback with Positive Epidermolysis Bullosa Data

BridgeBio Pharma and its affiliate Phoenix Tissue Repair announced positive data from their Phase II clinical trial for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).

May 20, 2022
·
3 min read
·
Hannah Chudleigh
Drug Development

Athersys Shares Pummeled as Ischemic Stroke Study Misses Endpoint

A study conducted by Athersys’ partner Healios on a potential treatment for ischemic stroke failed to meet the primary endpoint as its stock dropped 43%.

May 20, 2022
·
2 min read
·
Vanessa Doctor, RN
Drug Development

Following Patient Death, FDA Puts Foghorn Study on Partial Hold

The hold follows a serious adverse event in which a study participant died after developing possible differentiation syndrome.

May 20, 2022
·
2 min read
·
Jazmine Colatriano, M.S.